Pharmaceuticals

The Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Is Witnessing Impact From Rising Adoption Of Personalized Medicine To Drive Growth

May 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Projected Increase In Market Value Of The Phosphoinositide 3-Kinase (PI3K) Inhibitors Market During 2026–2030?

The phosphoinositide 3-kinase (pi3k) inhibitors market size has experienced swift expansion in recent years. It is projected to grow from $1.56 billion in 2025 to $1.76 billion in 2026, reflecting a compound annual growth rate (CAGR) of 13.2%. This historical growth can be primarily attributed to an escalating cancer prevalence, the approval of first-generation PI3K inhibitors, significant advances in molecular oncology, increased expenditure on oncology research and development, and the persistent unmet needs within hematologic malignancies.

The phosphoinositide 3-kinase (pi3k) inhibitors market size is projected to undergo significant expansion over the next few years. This market is expected to reach $2.88 billion by 2030, growing at a compound annual growth rate (CAGR) of 13.1%. The anticipated growth during the forecast period is primarily driven by the development of next-generation PI3K pipelines, the market’s expansion into autoimmune indications, improved safety profiles of treatments, the adoption of personalized oncology strategies, and an increase in combination therapy trials. Prominent trends observed in the forecast period include the widening availability of targeted cancer therapies, the growing development of isoform-selective inhibitors, an increasing utilization of combination oncology regimens, a heightened focus on biomarker-based patient selection, and a shift towards oral targeted therapies.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23474&type=smp

Which Important Drivers Are Guiding The Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Growth?

The rising incidence of cancer and autoimmune conditions is anticipated to propel the growth of the phosphoinositide 3-kinase (PI3K) inhibitors market in the future. Cancer involves a group of diseases marked by uncontrolled cell growth and proliferation, whereas autoimmune diseases develop when the body’s immune system mistakenly attacks its healthy tissues, resulting in chronic inflammation and tissue damage. This increasing prevalence of cancer and autoimmune diseases stems from heightened genetic predisposition, leading to accumulated genetic mutations and immune system dysregulation over time. Phosphoinositide 3-kinase (PI3K) inhibitors play a vital role in tackling the escalating occurrence of these diseases by targeting aberrant PI3K signaling, which is linked to tumor progression and immune dysfunction, thereby providing therapeutic advantages through precision medicine approaches that improve treatment efficacy and patient outcomes. For example, in May 2025, as per the National Cancer Institute, a US-based government agency, the count of cancer survivors in the United States stood at 18.1 million in 2022 and is forecast to increase to 22.5 million by 2032, with an estimated 40.5% of the population expected to receive a cancer diagnosis in their lifetime. Consequently, the increasing prevalence of cancer and autoimmune diseases drives the growth of the Phosphoinositide 3-Kinase (PI3K) Inhibitors market.

How Are Segments Identified Within The Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Segment Framework?

The phosphoinositide 3-kinase (pi3k) inhibitors market covered in this report is segmented –

1) By Type Of Inhibitor: Isoform Selective Inhibitors, Pan-Phosphoinositide 3-Kinase (PI3K) Inhibitors, Dual Phosphoinositide 3-Kinase (PI3K) Or Mechanistic Target Of Rapamycin (mTOR) Inhibitors, Novel Targeted Inhibitors

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channel

3) By Application Areas: Cancer Treatment, Metabolic Disorders, Autoimmune Diseases, Neurological Disorders

4) By End User: Hospitals, Research Institutes, Pharmaceutical Companies, Contract Research Organizations (CROs)

Subsegments:

1) By Isoform Selective Inhibitors: Phosphoinositide 3-Kinase Alpha (PI3Ka), Phosphoinositide 3-Kinase Beta (PI3Kß), Phosphoinositide 3-Kinase Delta (PI3Kd), Phosphoinositide 3-Kinase Gamma (PI3K?)

2) By Pan-Phosphoinositide 3-Kinase (PI3K) Inhibitors: Class I Phosphoinositide 3-Kinase (PI3K), Non-Isoform Specific Phosphoinositide 3-Kinase (PI3K), Phosphoinositide 3-Kinase Kinase Domain

3) By Dual Phosphoinositide 3-Kinase (PI3K) Or Mechanistic Target of Rapamycin (mTOR) Inhibitors: Phosphoinositide 3-Kinase (PI3K) and Mechanistic Target of Rapamycin (mTOR) Inhibition, Adenosine Triphosphate-Competitive Dual Inhibitors, Allosteric Dual Inhibitors

4) By Novel Targeted Inhibitors: Next-Generation Phosphoinositide 3-Kinase, Targeting Mutant Phosphoinositide 3-Kinase Isoforms, Combination Therapies

Which Trends Are Shaping The Phosphoinositide 3-Kinase (PI3K) Inhibitors Market?

Major companies in the phosphoinositide 3-kinase (PI3K) inhibitors market are concentrating on developing innovative solutions, such as PI3K delta inhibitor therapies, to offer a targeted treatment for conditions linked to dysregulated phosphoinositide 3-kinase (PI3K) signaling. Phosphoinositide 3-kinase (PI3K) delta inhibitor therapy is a precise treatment designed to block the PI3K delta enzyme, which is crucial in immune cell signaling, thereby reducing inflammation, autoimmune responses, and certain blood cancers. For example, in March 2023, the United States Food and Drug Administration (FDA), a US-based government regulatory agency, announced the approval of Joenja (leniolisib) as the initial treatment for activated phosphoinositide 3-kinase delta syndrome (APDS) in patients aged 12 years and older. This approval marked a significant advancement in targeted therapies by introducing a precision medicine approach to address immune dysfunction stemming from genetic mutations in the PIK3CD or PIK3R1 genes. The launch of Joenja (leniolisib) not only extends the clinical applications of phosphoinositide 3-kinase (PI3K) inhibitors beyond oncology but also emphasizes the growing focus on personalized treatments for rare immunological disorders.

Who Are The Companies Competing Within The Phosphoinositide 3-Kinase (PI3K) Inhibitors Market?

Major companies operating in the phosphoinositide 3-kinase (pi3k) inhibitors market are Novartis AG, Gilead Sciences Inc., TG Therapeutics Inc., Verastem Oncology Inc., Bayer AG, AstraZeneca PLC, Pfizer Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd, Genentech Inc., Takeda Pharmaceutical Company Limited, Incyte Corporation, Boehringer Ingelheim, Sanofi S.A., Bristol Myers Squibb, Eli Lilly and Company, Merck KGaA, Relay Therapeutics Inc., Ideaya Biosciences Inc., BeiGene Ltd.

Get The Full Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Report:

https://www.thebusinessresearchcompany.com/report/phosphoinositide-3-kinase-pi3k-inhibitors-global-market-report

Where Is The Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Most Concentrated Geographically?

North America was the largest region in the phosphoinositide 3-kinase (PI3K) inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the phosphoinositide 3-kinase (pi3k) inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/phosphoinositide-3-kinase-pi3k-inhibitors-global-market-report

Browse Through More Reports Similar to the Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market 2026, By The Business Research Company

Kinase Inhibitors Market Report 2026

https://www.thebusinessresearchcompany.com/report/kinase-inhibitors-global-market-report

Janus Kinase Jak Inhibitors Market Report 2026

https://www.thebusinessresearchcompany.com/report/janus-kinase-jak-inhibitors-global-market-report

Tyrosine Kinase Inhibitors Market Report 2026

https://www.thebusinessresearchcompany.com/report/tyrosine-kinase-inhibitors-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795